Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Trial Profile

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPHERE
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2017 New trial record
    • 24 May 2017 Trial design of the study presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top